Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy (QH103E) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT06838832 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT06838832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06838832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy (QH103E) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 27, 2025
Completion date
March 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell